CNTX (Context Therapeutics) Common Stock: $0.09 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CNTX Context Therapeutics Inc CNTX
24 GF Score
Price $0.60
! 1 Warning Sign
View Full Analysis

What is Context Therapeutics Common Stock?

Context Therapeutics CNTX +1.42% 24 Common Stock is $0.09 Mil as of Mar. 2026. GuruFocus rates CNTX with a GF Score™ of 24/100. The stock has 1 warning sign investors should review.

Context Therapeutics's quarterly common stock stayed the same from Sep. 2025 ($0.09 Mil) to Dec. 2025 ($0.09 Mil) and stayed the same from Dec. 2025 ($0.09 Mil) to Mar. 2026 ($0.09 Mil).

Context Therapeutics's annual common stock increased from Dec. 2023 ($0.02 Mil) to Dec. 2024 ($0.09 Mil) and increased from Dec. 2024 ($0.09 Mil) to Dec. 2025 ($0.09 Mil).

Context Therapeutics Common Stock Historical Data

* Premium members only.

The historical data trend for Context Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Context Therapeutics Common Stock Chart

Context Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Common Stock
Get a 7-Day Free Trial 0.02 0.02 0.02 0.09 0.09

Context Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 0.09 0.09 0.09 0.09
CNTX
24GF Score
Context Therapeutics Inc CNTX
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Context Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of $0.09 Mil mean?
Context Therapeutics (CNTX) has a Common Stock of $0.09 Mil as of Mar. 2026. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Context Therapeutics and its competitors.
Is Context Therapeutics' Common Stock too high?
Context Therapeutics' current Common Stock is $0.09 Mil. Overall, Context Therapeutics has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Context Therapeutics' Common Stock compare to INKT and XLO?
Context Therapeutics' Common Stock of $0.09 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Context Therapeutics and its competitors. Context Therapeutics's current Common Stock is $0.09 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Context Therapeutics stock overvalued right now?
Context Therapeutics (CNTX) has a current Common Stock of $0.09 Mil. The current Common Stock is $0.09 Mil. Context Therapeutics' overall GF Score™ is 24/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Context Therapeutics (CNTX), the current Common Stock is $0.09 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Context Therapeutics Business Description

Other Exchanges 6K9:Germany
Address 2001 Market Street, Suite 3915, Unit No. 15, Philadelphia, PA, USA, 19103
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
24GF Score

Get the complete analysis for CNTX

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.60
Price